Phase II Study of Paclitaxel Given Once per Week Along With Trastuzumab and Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

PURPOSE: The CLEOPATRA (Clinical Evaluation of Trastuzumab and Pertuzumab) study demonstrated superior progression-free survival (PFS) and overall survival when pertuzumab was added to trastuzumab and docetaxel. Paclitaxel given once per week is effective and less toxic than docetaxel. We performed...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Dang, Chau, Iyengar, Neil, Datko, Farrah, D'Andrea, Gabriella, Theodoulou, Maria, Dickler, Maura, Goldfarb, Shari, Lake, Diana, Fasano, Julie, Fornier, Monica, Gilewski, Theresa, Modi, Shanu, Gajria, Devika, Moynahan, Mary Ellen, Hamilton, Nicola, Patil, Sujata, Jochelson, Maxine, Norton, Larry, Baselga, José, Hudis, Clifford
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2015
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5747317/
https://ncbi.nlm.nih.gov/pubmed/25547504
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.57.1745
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados